Anti-emp2 therapy reduces cancer stem cells
US-2015329621-A1 · Nov 19, 2015 · US
Diagnostic tools for response to 6-thiopurine therapy
US10385395B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10385395-B2 |
| Application number | US-201314391814-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 11, 2013 |
| Priority date | Apr 11, 2012 |
| Publication date | Aug 20, 2019 |
| Grant date | Aug 20, 2019 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
NK cell licensing predisposes patients to chronic inflammatory disease. Methods and kits to diagnose and treat chronic inflammatory disease based on genetic haplotype and cytokine profile are described herein.
First claim
Opening claim text (preview).
We claim: 1. A method for treating a patient having a chronic inflammatory disease, the method comprising administering a 6-thiopurine or 6-thioguanine treatment regimen to the patient having the chronic inflammatory disease, wherein the patient is determined have a KIR/HLA-haplotype of an AA haplotype, homozygous for HLA-C1 and present for Bw6; a non-AA haplotype, present for KIR2DL2 and homozygous for HLA-C1; a non-AA haplotype, present for KIR2DL2 and heterozygous for HLA-C1/HLA-C2; or a non-AA haplotype, absent for KIR2DL2 and homozygous for HLA-C1, based on a KIR/HLA haplotype determination of the patient, and wherein the KIR/HLA-haplotype of the patient is determined by: (a) providing a biological sample from the patient; (b) obtaining nucleic acid from the biological sample; and (c) hybridizing the nucleic acid, to: (i) a first solid support comprising synthetic capture probes selective for KIR2DL3, KIR2DL1, KIR2DL4, KIR3DL1, KIR3DL2, KIR3DL3, KIR2DS4, KIR2DP1, KIR3DP1, KIR2DL5, KIR2DS1, KIR2DS2, KIR2DS3, KIR2DS5, and KIR3DS1; and (ii) a second solid support comprising capture probes selective for HLA-C1, HLA-C2, HLA-Bw4 and HLA-Bw6. 2. The method of claim 1 , wherein the biological sample is a blood sample. 3. The method of claim 1 , wherein the patient is a human. 4. The method of claim 1 , wherein the treatment regimen is a 6-thioguanine treatment regimen.
Assignees
Inventors
Classifications
Antineoplastic agents · CPC title
Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism · CPC title
- G01N33/6893Primary
related to diseases not provided for elsewhere · CPC title
Bowel diseases, e.g. Crohn, ulcerative colitis, IBS · CPC title
Haplotypes · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10385395B2 cover?
- NK cell licensing predisposes patients to chronic inflammatory disease. Methods and kits to diagnose and treat chronic inflammatory disease based on genetic haplotype and cytokine profile are described herein.
- Who is the assignee on this patent?
- Univ California
- What technology area does this patent fall under?
- Primary CPC classification G01N33/6893. Mapped technology areas include Physics.
- When was this patent published?
- Publication date Tue Aug 20 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 4 related publications on this page (citations in our corpus or others sharing the same primary CPC).